SUMMARY We evaluated the effect of dipyridamole on thallium-201 myocardial perfusion in 23 patients with progressive systemic sclerosis (PSS) with diffuse scleroderma. Thallium-201 single photon emission computed tomography (SPECT) was performed at rest and after coronary artery vasodilatation with intravenous dipyridamole (0-14 mg/kg/min for four minutes). The left myocardium was divided into nine segments; each segment was graded as 2-0, 1-5, 1.0, 0-5, 0 (zero represents no activity). Dipyridamole significantly improved resting thallium-201 myocardial perfusion: the mean (SD) number of segments with thallium defects decreased from 6*0 (2-1) at rest to 4.1 (2.5) after dipyridamole (p<0O0001); the mean (SD) score in segments with resting defects increased from 0-92 (0.24) at rest to 1-13 (0.38) after dipyridamole (p<00001); the mean (SD) global score per patient increased from 10.2 (1-8) at rest to 11.4 (2-1) after dipyridamole (p<002); the global score increased by at least 2.0 in 12 patients and worsened by at least 2.0 in three patients only (p=0-05).
may be the primary target organ in PSS and that the myocardial lesion is a manifestation of focal ischaemic injury resulting from functional vascular disease, with or without accompanying structural change.1-3 [8] [9] [10] [11] [12] [13] [14] Bulkley reported a high prevalence of myocardial contraction band necrosis-a histological lesion seen in the setting of ischaemic injury followed by reperfusion-and speculated that myocardial fibrosis results from intermittent spasm of the small coronary arteries, a form of 'myocardial Raynaud's phenomenon'.2 Additional support for this hypothesis has been provided by other investigators, who demonstrated cold induced abnormalities on thallium perfusion in patients with PSS. 12 Follansbee et al showed that the majority of patients with PSS and diffuse scleroderma had thallium-201 myocardial perfusion defects.13
Since abnormalities of small coronary arteries may have an important role in primary scleroderma 718 myocardial disease, vasodilator drugs could be beneficial in PSS patients with myocardial involvement. In the present study we evaluated the effect of the coronary vasodilator dipyridamole on thallium-201 myocardial perfusion in patients with diffuse scleroderma, using single photon emission computed tomography (SPECT).
Patients and methods PATIENTS WITH PROGRESSIVE SYSTEMIC

SCLEROSIS
Twenty three patients with PSS with diffuse scleroderma were studied. All patients satisfied the American Rheumatism Association preliminary criteria for definite systemic sclerosis. '5 In addition to skin thickening of the fingers, hands, and forearms, all patients also had truncal involvement (diffuse scleroderma). None of the patients had the CREST syndrome variant (calcinosis, Raynaud's phenomenon, oesophageal dOysmotility, sclerodactyly, telangiectasia) of PSS. ' Twenty one of the 23 patients were women. The mean age (SD) was 51-5 (8-5) years (range . The duration of disease ranged from one to 30 years (mean (SD) (9. 3) years). Patients were excluded if they had severe pulmonary or renal involvement. Twenty two patients had Raynaud's phenomenon, 10 of whom also had a history of digital ulcers. At the time of the study none of the patients was taking medication for cardiac or vascular disease. All Each image was interpreted by three independent experienced observers without knowledge of the patient's clinical history and catheterisation findings. The readers were blinded as to pre-and postdipyridamole scans. Such a qualitative interpretation of thallium images by multiple observers is a highly sensitive and specific test for coronary artery disease.
The analysis was done by visual inspection of the left anterior oblique sets of images, using the three most central slices of the left ventricle (apical, central, and basal). Each of these three slices was divided into three segments (Fig. 1) (14) [imol/l).
RESTING RADIONUCLIDE VENTRICULOGRAPHY
Resting left ventricular ejection fraction, assessed by radionuclide ventriculography, was normal in all but three PSS patients (mean (SD) 62(8)%, range 49-77%) ( Table 1) . Ten patients had hypokinetic regional left ventricular wall motion at rest. All regional wall motion--abnormalities were associated with resting thallium defects in the same territories.
RESTING AND DIPYRIDAMOLE THALLIUM-201 IMAGING
The results are shown in Table 1 .
All 23 PSS patients had abnormalities on resting thallium scans. Since the -left myocardium was divided into nine segments in each of the 23 patients a total of 207 segments was studied. Resting thallium defects were found in 138 segments (67%). The mean (SD) number of resting thallium defects in each patient was 6-0 (2-1) (range 2-9; with a median defect number of 6-0 for all 23 patients).
After dipyridamole infusion 55 thallium defects (40%) were improved (increase in mean score of 30.5) (14%) worsened (decrease in mean score of 30.5). Improvement induced by dipyridamole in a representative patient is shown in Fig. 2 .
In each patient an 'improvement index' was calculated as the ratio:
number of improved segments-number of worsened segments number of segments with resting thallium defects
The mean (SD) 'improvement index' (0-27 (0-47)) was significantly different from 0 (p<0.02, by the t test). After dipyridamole infusion 43 of the 55 improved segments had a score of B1-5 and were considered to be normal. Thus the mean (SD) number of segments with thallium defects significantly decreased from 6-0 (2-1) at rest to 4-1 (2-5) after dipyridamole (p<0O0001 by the paired t test).
In the 138 segments with resting thallium defects the mean (SD) score significantly increased from 0-92 (0.24) at rest to 1-13 (0.38) after dipyridamole (p<0O0001, by the paired t test).
The mean (SD) global score significantly increased from 10-2 (1.8) at rest to 11-4 (2.1) after dipyridamole (p<0-02, by the paired t test).
After dipyridamole the global score improved by at least 2*0 in 12 patients and worsened by at least 2*0 in three patients only (p=0-05, by the sign test).
Thus dipyridamole significantly improved all parameters of myocardial perfusion in patients with PSS and diffuse scleroderma.
The thallium results did not correlate with the age of the patients, or with the disease duration, or the resting left ventricular ejection fraction. The differences in thallium results were not statistically significant between patients with chest pain, or interstitial markings, or abnormal pulmonary function findings, and the remainder. Patients with electrocardiogram (ECG) abnormalities, however, had significantly greater numbers of resting thallium defects than did the remainder (mean (SD) (0-7) v 5*4 (2-1), p<0-0003). Patients with hypokinetic regional wall motion had significantly greater numbers of resting thallium defects and lower resting global scores than did the remainder (mean (SD) 7-2 (2.0) v 5-1 (1-8), p<002; and 9-1 (1.7) v .0*t) (1.5), p<O0Ol respectively Eight of the nine patients who underwent cardiac catheterisation had normal left ventricular function. In one patient the left ventricular end diastolic volume and left ventricular mass were increased to 109 ml/m2 and 107 g/m2 respectively, and ejection fraction decreased to 46%. The coronary arteriogram results were normal in all but one patient, who had 80% stenosis of a small lateral artery. This stenosis did not correlate with a thallium perfusion defect (at rest or after dipyridamole) or with a wall motion abnormality. Two of the three patients with dipyridamole induced aggravation in thallium defects underwent cardiac catheterisation and had normal coronary angiography.
Discussion
The major observation in this study was that dipyridamole significantly improved thallium-201 myocardial perfusion in patients with progressive systemic sclerosis with diffuse scleroderma. After dipyridamole infusion the mean number of segments with thallium defects significantly decreased, the mean score of segments with resting thallium defects and the mean global score significantly increased.
These findings are consistent with clinical and histopathological results, suggesting an abnormality of the small coronary arteries in primary scleroderma myocardial disease. Symptoms of PSMD include chest pain, dyspnoea, palpitations, congestive heart failure, syncope, and sudden death. - 13 These investigators used exercise and redistribution thallium-201 planar scintigraphy. 13 The present study is the first to use thallium-201 myocardial single photon emission computed tomography to assess the effect of dipyridamole on myocardial perfusion in systemic sclerosis. Emission tomography provides a better sensitivity and also a better interobserver agreement than planar scintigraphy in the detection of transmural myocardial necrosis with thallium-201.19 2() Furthermore, since histological lesions are small and patchy in primary scleroderma myocardial disease, emission tomography appears to be a more sensitive method than planar scintigraphy (which does not resolve depth) in these patients. Indeed, we found a very high prevalence of resting thallium defects in PSS patients.
Patients with abnormalities on ECG had significantly greater numbers of resting thallium defects than did the remainder. These findings are consistent with those of a recent study which showed that thallium defect scores were greater in PSS patients with septal infarction pattern or ventricular conduction abnormalities than in the remainder.29
Patients with hypokinetic regional wall motion had significantly greater numbers of resting thallium defects and lower resting global scores than did the remainder. These results are consistent with the hypothesis that myocardial dysfunction in these patients may be related to both fibrotic and vascular abnormalities. The present findings are in marked contrast with those usually obtained in patients with coronary artery disease. We showed that dipyridamole significantly improved thallium-201 myocardial perfusion abnormalities in PSS patients. It should be noted that patients with the best dipyridamole induced improvement had the lowest resting global scores. These findings may be explained by a high prevalence of reversible (vascular) abnormalities, suggesting that vasodilator drugs may be beneficial even in PSS patients with severe thallium-201 perfusion abnormalities at rest. The mechanism of action of dipyridamole on thallium-201 myocardial perfusion defects in our patients cannot be determined from this study. These results, however, are compatible with the hypothesis that the previously discussed abnormalities may coexist in variable proportions in different myocardial segments and patients. A resting thallium defect due to vasospasm of the small coronary arteries may be improved after coronary artery dilatation with dipyridamole. The hypothesis that the dipyridamole induced increased perfusion of normal areas surrounding some defects might make defects appear to diminish, while in fact the perfusion of the fibrotic areas may not be changed, cannot be excluded; however, this possibility is considerably reduced by the tomographic technique, as compared with planar scintigraphy. Conversely, resting thallium defects due to fibrosis or to anatomical lesions of the intramyocardial vasculature may be unchanged or even aggravated after dipyridamole, as previously described in patients with severe atherosclerotic stenoses of the large coronary arteries.34 35 The results of the present study demonstrate that dipyridamole significantly improves thallium-201 myocardial perfusion in patients with progressive systemic sclerosis with diffuse scleroderma. A long term controlled study of small coronary artery vasodilator drugs in the treatment of PSS patients with myocardial perfusion abnormalities is warranted.
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